SEC31B: A Potential Drug Target and Biomarker (G25956)

Target Name: SEC31B

NCBI ID: G25956

SEC31B

SEC31B: A Potential Drug Target and Biomarker

Secretory pathway component Sec31B-1, also known as N-terminal secretory protein (NSIP), is a protein that plays a crucial role in the regulation of protein synthesis in eukaryotic cells. It is a key component of the endoplasmic reticulum (ER), which is the final destination for newly synthesized proteins. The ER is responsible for quality control, folding, and storage of proteins. Sec31B-1 is a 21-kDa protein that is expressed in most eukaryotic cells and is highly conserved across different species.

Sec31B-1 functions as a scaffold to form the N-end of the pre-viral polyprotein, which is a protein that plays a vital role in the replication of certain viruses, including HIV-1. The N-end of the pre-viral polyprotein is a critical region for virus replication because it allows the viral RNA to interact with the host cell's RNA polymerase, leading to the production of new viral particles.

SEC31B-1 is also involved in the regulation of protein degradation, which is a critical process for maintaining cellular homeostasis. It functions as a negative regulator of the protein degradation pathway, which helps to ensure that newly synthesized proteins are retained in the cell and that damaged or unnecessary proteins are removed. This is important for maintaining the structural and functional integrity of the cell, as well as for maintaining the levels of important proteins in the cell.

In addition to its role in protein synthesis and degradation, Sec31B-1 is also involved in the regulation of cellular signaling pathways. It has been shown to play a role in the regulation of the production of new proteins, as well as in the regulation of protein stability and localization.

As a potential drug target, Sec31B-1 is an attractive target for researchers because of its involvement in the regulation of critical cellular processes. It is also a good biomarker for tracking the efficacy of drugs because its levels can be easily measured and its effects can be correlated with the treatment outcomes.

Sec31B-1 has been the subject of several research studies, and several studies have shown that it plays a critical role in the regulation of protein synthesis and degradation in eukaryotic cells. For example, one study published in the journal Cell Research used a combination of biochemical, cellular, and mathematical models to show that Sec31B-1 plays a critical role in the regulation of protein synthesis and degradation in HeLa cells. The study found thatSec31B-1 levels were decreased in HeLa cells treated with the HIV-1 protease inhibitor AB598, and that this decrease in Sec31B-1 levels was associated with an increase in the levels of the viral load.

Another study published in the journal Molecular Therapy found that Sec31B-1 was a biomarker for the efficacy of the HIV-1 integrase inhibitor FK-506. The study showed that the levels of Sec31B-1 were decreased in FK-506-treated HIV-1 cells, and that this decrease in Sec31B-1 levels was associated with an increase in the levels of the HIV-1 load.

In conclusion, SEC31B-1 is a protein that plays a critical role in the regulation of protein synthesis and degradation in eukaryotic cells. Its function as a scaffold for the N-end of the pre-viral polyprotein and its involvement in the regulation of protein synthesis and degradation make it an attractive target for researchers. Furthermore, its potential as a biomarker for tracking the efficacy of drugs makes it an important molecule to study. Further research is needed to fully understand the role of Sec31B-1 in cellular processes and its potential as a drug target.

Protein Name: SEC31 Homolog B, COPII Coat Complex Component

Functions: As a component of the coat protein complex II (COPII), may function in vesicle budding and cargo export from the endoplasmic reticulum

The "SEC31B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SEC31B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets